Astrazeneca Drug Patent Portfolio
Astrazeneca owns 23 orange book drugs protected by 178 US patents with Airsupra having the least patent protection, holding only 1 patent. And Symbicort with maximum patent protection, holding 33 patents. Given below is the list of Astrazeneca's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11970530 | Methods of treating homologous recombination deficient cancer | 25 Oct, 2041 | Active |
| US10300065 | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction | 27 Jul, 2036 | Active |
| US10167291 | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | 01 Jul, 2036 | Active |
| US11059829 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate | 01 Jul, 2036 | Active |
| US9796721 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | 01 Jul, 2036 | Active |
| US10300065 | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction | 27 Jan, 2036 | Active |
| US10300087 | Extended use zirconium silicate compositions and methods of use thereof | 14 Oct, 2035 | Active |
| US11738044 | Extended use zirconium silicate compositions and methods of use thereof | 14 Oct, 2035 | Active |
| US9592253 | Extended use zirconium silicate compositions and methods of use thereof | 14 Oct, 2035 | Active |
| US10272083 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | 21 Jan, 2035 | Active |
| US11771696 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | 21 Jan, 2035 | Active |
| US10183020 | Pharmaceutical compositions comprising AZD9291 | 02 Jan, 2035 | Active |
| US10695365 | Microporous zirconium silicate for the treatment of hyperkalemia | 22 Oct, 2033 | Active |
| US8877255 | Microporous zirconium silicate for the treatment of hyperkalemia | 22 Oct, 2033 | Active |
| US9913860 | Microporous zirconium silicate for the treatment of hyperkalemia | 22 Oct, 2033 | Active |
| US10039766 | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide | 16 Apr, 2033 | Active |
| US9487525 | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide | 16 Apr, 2033 | Active |
| US10117844 | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | 04 Jan, 2033 | Active |
| US9050308 | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | 04 Jan, 2033 | Active |
| US9050309 | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | 04 Jan, 2033 | Active |
| US8946235 | 2-(2,4,5-substituted-anilino) pyrimidine compounds | 08 Aug, 2032 | Active |
| US11524951 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | 25 Jul, 2032 | Active |
| US9732058 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | 25 Jul, 2032 | Active |
| US10239883 | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors | 11 Jul, 2032 | Active |
| US9290504 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors | 11 Jul, 2032 | Active |
| US9758524 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | 11 Jul, 2032 | Active |
| US8802152 | Microporous zirconium silicate for the treatment of hyperkalemia | 19 Apr, 2032 | Active |
| US10335432 | Microporous zirconium silicate for the treatment of hyperkalemia | 10 Feb, 2032 | Active |
| US10398730 | Microporous zirconium silicate for the treatment of hyperkalemia | 10 Feb, 2032 | Active |
| US10413569 | Microporous zirconium silicate for the treatment of hyperkalemia | 10 Feb, 2032 | Active |
| US11406662 | Microporous zirconium silicate for the treatment of hyperkalemia | 10 Feb, 2032 | Active |
| US8808750 | Microporous zirconium silicate for the treatment of hyperkalemia | 10 Feb, 2032 | Active |
| US9844567 | Microporous zirconium silicate for the treatment of hyperkalemia | 10 Feb, 2032 | Active |
| US9861658 | Microporous zirconium silicate for the treatment of hyperkalemia | 10 Feb, 2032 | Active |
| US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer | 04 Aug, 2031 | Active |
| US8815258 | Compositions, methods and systems for respiratory delivery of two or more active agents | 17 Mar, 2031 | Active |
| US8425934 | Pharmaceutical compositions | 17 Oct, 2030 | Active |
| US9415009 | Compositions, methods and systems for respiratory delivery of two or more active agents | 28 May, 2030 | Active |
| US10716753 | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems | 28 May, 2030 | Active |
| US8324266 | Compositions, methods and systems for respiratory delivery of two or more active agents | 28 May, 2030 | Active |
| US8703806 | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents | 28 May, 2030 | Active |
| US8808713 | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems | 28 May, 2030 | Active |
| US9463161 | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems | 28 May, 2030 | Active |
| US8425934 | Pharmaceutical compositions | 17 Apr, 2030 | Active |
| US8101623 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | 10 Mar, 2030 | Active |
| US8475842 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | 31 Dec, 2029 | Active |
| US11633396 | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one | 07 Oct, 2029 | Active |
| US11975001 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | 07 Oct, 2029 | Active |
| US12048695 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | 07 Oct, 2029 | Active |
| US8616196 | Inhalation device and a method for assembling said inhalation device | 07 Oct, 2029 | Active |
| US8528545 | Inhaler device that reduces the risk for miscounting a dosage | 16 Apr, 2029 | Active |
| US8616196 | Inhalation device and a method for assembling said inhalation device | 07 Apr, 2029 | Active |
| US11813246 | Pharmaceutical composition | 26 Mar, 2029 | Active |
| US8528545 | Inhaler device that reduces the risk for miscounting a dosage | 16 Oct, 2028 | Active |
| US10059714 | Protein kinase B inhibitors | 10 Oct, 2028 | Active |
| US10654855 | Protein kinase B inhibitors | 10 Oct, 2028 | Active |
| US11760760 | Protein kinase B inhibitors | 10 Oct, 2028 | Active |
| US8247416 | Phthalazinone derivative | 24 Sep, 2028 | Active |
| US8387615 | Inhaler cap strap | 26 Sep, 2027 | Active |
| US7449464 | Phthalazinone derivatives | 08 Sep, 2027 | Active |
| US8071579 | DNA damage repair inhibitors for the treatment of cancer | 12 Aug, 2027 | Active |
| US8143241 | DNA damage repair inhibitors for treatment of cancer | 12 Aug, 2027 | Active |
| US8387615 | Inhaler cap strap | 26 Mar, 2027 | Active |
| US7960370 | Type A gelatin capsule containing PUFA in free acid form | 20 Dec, 2026 | Active |
| US9156795 | Hydrogen sulfate salt | 12 Dec, 2026 | Active |
| US9562017 | Hydrogen sulfate salt | 12 Dec, 2026 | Active |
| US7459554 | Imidazopyrazine tyrosine kinase inhibitors | 24 Nov, 2026 | Active |
| US7587988 | Inhaler device counter | 10 Oct, 2026 | Active |
| US7587988 | Inhaler device counter | 10 Apr, 2026 | Active |
| US8809336 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | 25 Oct, 2025 | Active |
| US9006430 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein | 25 Oct, 2025 | Active |
| US8875699 | Inhaler cap strap | 10 May, 2025 | Active |
| USRE46276 | Triazolo(4,5-D)pyrimidine compounds | 30 Apr, 2025 | Active |
| US7425637 | N3 alkylated benzimidazole derivatives as MEK inhibitors | 13 Mar, 2025 | Active |
| US8178693 | N3 alkylated benzimidazole derivatives as MEK inhibitors | 13 Mar, 2025 | Active |
| US8383678 | Type a gelatin capsule containing PUFA in free acid form | 07 Feb, 2025 | Active |
| US9012501 | Type A gelatin capsule containing PUFA in free acid form | 07 Feb, 2025 | Active |
| US9132112 | Type A gelatin capsule containing PUFA in free acid form | 07 Feb, 2025 | Active |
| US8875699 | Inhaler cap strap | 10 Nov, 2024 | Expired |
| USRE46276 | Triazolo(4,5-D)pyrimidine compounds | 30 Oct, 2024 | Expired |
| US7981889 | Phthalazinone derivatives | 11 Oct, 2024 | Expired |
| US8912187 | Phthalazinone derivatives | 12 Mar, 2024 | Expired |
| US9169235 | Phthalazinone derivatives | 12 Mar, 2024 | Expired |
| US9566276 | Phthalazinone derivatives | 12 Mar, 2024 | Expired |
| US8536206 | Process for the preparation of roflumilast | 08 Mar, 2024 | Expired |
| US8604064 | Process for the preparation of roflumilast | 08 Mar, 2024 | Expired |
| US8618142 | Process for the preparation of roflumilast | 08 Mar, 2024 | Expired |
| US10166247 | Composition for inhalation | 29 Jul, 2023 | Expired |
| US11311558 | Composition for inhalation | 29 Jul, 2023 | Expired |
| US7759328 | Composition for inhalation | 29 Jul, 2023 | Expired |
| US8143239 | Composition for inhalation | 29 Jul, 2023 | Expired |
| US8575137 | Composition for inhalation | 29 Jul, 2023 | Expired |
| US8431154 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient | 19 Feb, 2023 | Expired |
| US9468598 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient | 19 Feb, 2023 | Expired |
| US10166247 | Composition for inhalation | 29 Jan, 2023 | Expired |
| US11311558 | Composition for inhalation | 29 Jan, 2023 | Expired |
| US7759328 | Composition for inhalation | 29 Jan, 2023 | Expired |
| US8143239 | Composition for inhalation | 29 Jan, 2023 | Expired |
| US8575137 | Composition for inhalation | 29 Jan, 2023 | Expired |
| US7151102 | Phthalazinone derivatives | 29 Apr, 2022 | Expired |
| US7967011 | Inhalation device | 11 Feb, 2022 | Expired |
| US7967011 | Inhalation device | 11 Aug, 2021 | Expired |
| US7265124 | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound | 09 Jul, 2021 | Expired |
| US6774122 | Formulation | 09 Jul, 2021 | Expired |
| US7456160 | Formulation | 09 Jul, 2021 | Expired |
| US8329680 | Formulation | 09 Jul, 2021 | Expired |
| US8466139 | Formulation | 09 Jul, 2021 | Expired |
| US6774122 | Formulation | 09 Jan, 2021 | Expired |
| US7456160 | Formulation | 09 Jan, 2021 | Expired |
| US8329680 | Formulation | 09 Jan, 2021 | Expired |
| US8466139 | Formulation | 09 Jan, 2021 | Expired |
| US5792795 | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids | 13 May, 2020 | Expired |
| US5948818 | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids | 13 May, 2020 | Expired |
| US6428810 | Pharmaceutical formulation comprising omeprazole | 03 May, 2020 | Expired |
| US5712298 | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors | 27 Jan, 2020 | Expired |
| US6525060 | Triazolo(4,5-d)pyrimidine compounds | 02 Dec, 2019 | Expired |
| US7250419 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | 02 Dec, 2019 | Expired |
| US6403616 | Chemical process and pharmaceutical formulation | 15 Nov, 2019 | Expired |
| US6428810 | Pharmaceutical formulation comprising omeprazole | 03 Nov, 2019 | Expired |
| US6598603 | Method for treating respiratory diseases | 23 Jun, 2019 | Expired |
| US6899099 | Method for treating a respiratory disease | 23 Jun, 2019 | Expired |
| US7524834 | Sterile powders, formulations, and methods for producing the same | 11 May, 2019 | Expired |
| US7367333 | Inhalation device | 11 May, 2019 | Expired |
| US6150380 | Crystalline form of omeprazole | 10 May, 2019 | Expired |
| US6147103 | Omeprazole process and compositions thereof | 09 Apr, 2019 | Expired |
| US6166213 | Omeprazole process and compositions thereof | 09 Apr, 2019 | Expired |
| US6191148 | Omerazole process and compositions thereof | 09 Apr, 2019 | Expired |
| US6332985 | Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions | 29 Mar, 2019 | Expired |
| US7897646 | Use for budesonide and formoterol | 09 Mar, 2019 | Expired |
| US8461211 | Use for budesonide and formoterol | 09 Mar, 2019 | Expired |
| US6598603 | Method for treating respiratory diseases | 23 Dec, 2018 | Expired |
| US6899099 | Method for treating a respiratory disease | 23 Dec, 2018 | Expired |
| US6369085 | Form of S-omeprazole | 25 Nov, 2018 | Expired |
| US7411070 | Form of S-omeprazole | 25 Nov, 2018 | Expired |
| US8466175 | Form of S-omeprazole | 25 Nov, 2018 | Expired |
| US7524834 | Sterile powders, formulations, and methods for producing the same | 11 Nov, 2018 | Expired |
| US7367333 | Inhalation device | 11 Nov, 2018 | Expired |
| US6150380 | Crystalline form of omeprazole | 10 Nov, 2018 | Expired |
| US6147103 | Omeprazole process and compositions thereof | 09 Oct, 2018 | Expired |
| US6166213 | Omeprazole process and compositions thereof | 09 Oct, 2018 | Expired |
| US6191148 | Omerazole process and compositions thereof | 09 Oct, 2018 | Expired |
| US7897646 | Use for budesonide and formoterol | 09 Sep, 2018 | Expired |
| US8461211 | Use for budesonide and formoterol | 09 Sep, 2018 | Expired |
| US6251910 | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists | 15 Jul, 2018 | Expired |
| US6369085 | Form of S-omeprazole | 25 May, 2018 | Expired |
| US7411070 | Form of S-omeprazole | 25 May, 2018 | Expired |
| US8466175 | Form of S-omeprazole | 25 May, 2018 | Expired |
| US6123924 | Pressurized aerosol inhalation compositions | 26 Mar, 2018 | Expired |
| US5948437 | Pharmaceutical compositions using thiazepine | 28 Nov, 2017 | Expired |
| US6291445 | Low dose budesonide formulations and uses thereof | 29 Oct, 2017 | Expired |
| US6686346 | Formulation | 29 Oct, 2017 | Expired |
| US6986904 | Formulation | 29 Oct, 2017 | Expired |
| US6123924 | Pressurized aerosol inhalation compositions | 26 Sep, 2017 | Expired |
| US5948437 | Pharmaceutical compositions using thiazepine | 28 May, 2017 | Expired |
| US5770599 | Quinazoline derivatives | 05 May, 2017 | Expired |
| US6291445 | Low dose budesonide formulations and uses thereof | 29 Apr, 2017 | Expired |
| US6686346 | Formulation | 29 Apr, 2017 | Expired |
| US6986904 | Formulation | 29 Apr, 2017 | Expired |
| US5900424 | Omeprazole magnesium salt form | 04 Nov, 2016 | Expired |
| US5900424 | Omeprazole magnesium salt form | 04 May, 2016 | Expired |
| US5817338 | Multiple unit tableted dosage form of omeprazole | 06 Oct, 2015 | Expired |
| US5714504 | Compositions | 03 Aug, 2015 | Expired |
| US5753265 | Multiple unit pharmaceutical preparation | 07 Jun, 2015 | Expired |
| US5690960 | Pharmaceutical formulation of omeprazole | 25 May, 2015 | Expired |
| US5714504 | Compositions | 03 Feb, 2015 | Expired |
| US5877192 | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole | 27 Nov, 2014 | Expired |
| US6875872 | Compounds | 27 Nov, 2014 | Expired |
| US5690960 | Pharmaceutical formulation of omeprazole | 25 Nov, 2014 | Expired |
| US5674860 | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders | 07 Oct, 2014 | Expired |
| US5877192 | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole | 27 May, 2014 | Expired |
| US6875872 | Compounds | 27 May, 2014 | Expired |
| US6143771 | Compounds | 27 May, 2014 | Expired |
| US5466699 | Indolyl compounds for treating migraine | 14 May, 2013 | Expired |
| US5457105 | Quinazoline derivatives useful for treatment of neoplastic disease | 19 Jan, 2013 | Expired |
| US5616582 | Quinazoline derivatives as anti-proliferative agents | 19 Jan, 2013 | Expired |
| US5972919 | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof | 17 Dec, 2012 | Expired |
| US5466699 | Indolyl compounds for treating migraine | 14 Nov, 2012 | Expired |
| US6641800 | Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane | 23 Sep, 2012 | Expired |
Latest Legal Activities on Astrazeneca's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Astrazeneca.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Jul, 2024 | US9562017 |
|
Petition to Accept Late Payment of Maintenance Fee Payment Filed
Critical
| 24 Jun, 2024 | US8178693 |
|
Expire Patent
Critical
| 17 Jun, 2024 | US8178693 |
|
Maintenance Fee Reminder Mailed
Critical
| 10 Jun, 2024 | US9468598 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 May, 2024 | US8324266 |
| Second letter to regulating agency to determine regulatory review period | 16 May, 2024 | US8101623 |
| Second letter to regulating agency to determine regulatory review period | 16 May, 2024 | US10059714 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 May, 2024 | US10059714 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 May, 2024 | US8101623 |
|
Withdrawal of Application for PTE
Critical
| 06 May, 2024 | US8802152 |
|
Patent Term Extension Certificate
Critical
| 06 May, 2024 | US8808750 |
|
Expire Patent
Critical
| 29 Apr, 2024 | US8143239 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Apr, 2024 | US9487525 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Mar, 2024 | US9463161 |
| Patent eCofC Notification | 26 Mar, 2024 | US11771696 |
Astrazeneca's Drug Patent Litigations
Astrazeneca's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 11, 2011, against patent number US8859562. The petitioner , challenged the validity of this patent, with Thomas Helleday as the respondent. Click below to track the latest information on how companies are challenging Astrazeneca's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10272083 | February, 2023 |
Institution Denied
(07 Aug, 2023)
| Acerta Pharma B.V. et al. | Sandoz Inc. |
| US6774122 | August, 2017 |
Terminated-Denied
(11 Dec, 2017)
| AstraZeneca AB | Fresenius Kabi USA,LLC |
| US8329680 | August, 2017 |
Terminated-Denied
(11 Dec, 2017)
| AstraZeneca AB | Fresenius Kabi USA, LLC |
| US8466139 | August, 2017 |
Terminated-Denied
(11 Dec, 2017)
| AstraZeneca AB | FRESENIUS KABI USA, LLC |
| US6774122 | February, 2017 |
Terminated-Denied
(30 Aug, 2017)
| AstraZeneca AB | InnoPharma Licensing LLC |
| US8329680 | February, 2017 |
Terminated-Denied
(30 Aug, 2017)
| AstraZeneca AB | InnoPharma Licensing LLC |
| US8466139 | February, 2017 |
Terminated-Denied
(30 Aug, 2017)
| AstraZeneca AB | InnoPharma Licensing LLC |
| US7759328 | January, 2017 |
Terminated-Denied
(24 Jul, 2017)
| AstraZeneca AB | Complex Innovations, LLC |
| US6774122 | June, 2016 |
Terminated-Settled
(10 Jan, 2017)
| AstraZeneca AB | Mylan Pharmaceuticals Inc. |
| US7456160 | June, 2016 |
Terminated-Settled
(10 Jan, 2017)
| AstraZeneca AB | Mylan Pharmaceuticals Inc. |
| US8466139 | June, 2016 |
Terminated-Settled
(10 Jan, 2017)
| AstraZeneca AB | Mylan Pharmaceuticals Inc. |
| US8329680 | June, 2016 |
Terminated-Denied
(14 Dec, 2016)
| AstraZeneca AB | Mylan Pharmaceuticals Inc. |
| US8859562 | October, 2011 |
Decision
(25 Mar, 2014)
| Thomas Helleday | |
Astrazeneca Drug Patents' Oppositions Filed in EPO
Astrazeneca drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 25, 2009, by Norton Healthcare Limited. This opposition was filed on patent number EP03703575A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP16735945A | Jan, 2021 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP12744254A | Aug, 2019 | Sandoz AG | Granted and Under Opposition |
| EP12744254A | Aug, 2019 | Galenicum Health S.L.U. | Granted and Under Opposition |
| EP12744254A | Aug, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP15192658A | Jul, 2018 | Generics (U.K.) Limited | Opposition rejected |
| EP15177189A | Apr, 2018 | Generics [UK] Limited (trading as Mylan) | Revoked |
| EP07794121A | Dec, 2017 | Generics [UK] Limited (trading as Mylan) | Revoked |
| EP07794121A | Dec, 2017 | Hexal Biotech GmbH | Revoked |
| EP07794121A | Dec, 2017 | Wittkopp, Alexander | Revoked |
| EP09740728A | Apr, 2017 | Teva Pharmaceutical Industries Ltd | Patent maintained as amended |
| EP12759801A | Oct, 2016 | STADA Arzneimittel AG | Opposition rejected |
| EP10173234A | Feb, 2014 | Generics [UK] Limited | Revoked |
| EP10173234A | Feb, 2014 | Hexal AG | Revoked |
| EP03704652A | Dec, 2012 | Hexal AG | Revoked |
| EP04798705A | May, 2012 | Adams, Harvey Vaughan John | Opposition procedure closed |
| EP04798705A | May, 2012 | STRAWMAN LIMITED | Opposition procedure closed |
| EP04743564A | Apr, 2012 | STRAWMAN LIMITED | Patent maintained as amended |
| EP04743564A | Apr, 2012 | Adams, Harvey Vaughan John | Patent maintained as amended |
| EP05702139A | Nov, 2010 | S P A SOCIETA' PRODOTTI ANTIBIOTICI S.p.a. | Patent maintained as amended |
| EP05702139A | Nov, 2010 | Pronova Biopharma Norge AS | Patent maintained as amended |
| EP05702139A | Nov, 2010 | Catalent Pharma Solutions, Inc. | Patent maintained as amended |
| EP03703575A | Nov, 2009 | NORTON HEALTHCARE LIMITED | Revoked |
Astrazeneca's Family Patents
Astrazeneca drugs have patent protection in a total of 69 countries. It's US patent count contributes only to 16.3% of its total global patent coverage. 13 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Astrazeneca Drug List
Given below is the complete list of Astrazeneca's drugs and the patents protecting them.
1. Airsupra
Airsupra is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9415009 | Compositions, methods and systems for respiratory delivery of two or more active agents |
28 May, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Airsupra's drug page
2. Bevespi Aerosphere
Bevespi Aerosphere is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8815258 | Compositions, methods and systems for respiratory delivery of two or more active agents |
17 Mar, 2031
(6 years from now)
| Active |
| US10716753 | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
28 May, 2030
(5 years from now)
| Active |
| US8324266 | Compositions, methods and systems for respiratory delivery of two or more active agents |
28 May, 2030
(5 years from now)
| Active |
| US8703806 | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
28 May, 2030
(5 years from now)
| Active |
| US8808713 | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
28 May, 2030
(5 years from now)
| Active |
| US9415009 | Compositions, methods and systems for respiratory delivery of two or more active agents |
28 May, 2030
(5 years from now)
| Active |
| US9463161 | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
28 May, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bevespi Aerosphere's drug page
3. Brilinta
Brilinta is protected by 10 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10300065
(Pediatric)
| Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
27 Jul, 2036
(11 years from now)
| Active |
| US10300065 | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
27 Jan, 2036
(11 years from now)
| Active |
| US8425934
(Pediatric)
| Pharmaceutical compositions |
17 Oct, 2030
(5 years from now)
| Active |
| US8425934 | Pharmaceutical compositions |
17 Apr, 2030
(5 years from now)
| Active |
| USRE46276
(Pediatric)
| Triazolo(4,5-D)pyrimidine compounds |
30 Apr, 2025
(4 months from now)
| Active |
| USRE46276 | Triazolo(4,5-D)pyrimidine compounds |
30 Oct, 2024
(a month ago)
| Expired |
| US7265124 | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
09 Jul, 2021
(3 years ago)
| Expired |
| US6525060 | Triazolo(4,5-d)pyrimidine compounds |
02 Dec, 2019
(5 years ago)
| Expired |
| US7250419 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
02 Dec, 2019
(5 years ago)
| Expired |
| US6251910 | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
15 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brilinta's drug page
4. Calquence
Calquence is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10167291 | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
01 Jul, 2036
(11 years from now)
| Active |
| US11059829 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate |
01 Jul, 2036
(11 years from now)
| Active |
| US9796721 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
01 Jul, 2036
(11 years from now)
| Active |
| US10272083 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
21 Jan, 2035
(10 years from now)
| Active |
| US11771696 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
21 Jan, 2035
(10 years from now)
| Active |
| US10239883 | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
11 Jul, 2032
(7 years from now)
| Active |
| US9290504 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
11 Jul, 2032
(7 years from now)
| Active |
| US9758524 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
11 Jul, 2032
(7 years from now)
| Active |
| US7459554 | Imidazopyrazine tyrosine kinase inhibitors |
24 Nov, 2026
(1 year, 11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Calquence's drug page
5. Daliresp
Daliresp is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8536206 | Process for the preparation of roflumilast |
08 Mar, 2024
(9 months ago)
| Expired |
| US8604064 | Process for the preparation of roflumilast |
08 Mar, 2024
(9 months ago)
| Expired |
| US8618142 | Process for the preparation of roflumilast |
08 Mar, 2024
(9 months ago)
| Expired |
| US8431154 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
19 Feb, 2023
(1 year, 10 months ago)
| Expired |
| US9468598 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
19 Feb, 2023
(1 year, 10 months ago)
| Expired |
| US5712298 | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
27 Jan, 2020
(4 years ago)
| Expired |
| US5712298 | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
27 Jan, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daliresp's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Epanova
Epanova is protected by 9 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10117844 | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
04 Jan, 2033
(8 years from now)
| Active |
| US9050308 | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
04 Jan, 2033
(8 years from now)
| Active |
| US9050309 | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
04 Jan, 2033
(8 years from now)
| Active |
| US7960370 | Type A gelatin capsule containing PUFA in free acid form |
20 Dec, 2026
(1 year, 11 months from now)
| Active |
| US8383678 | Type a gelatin capsule containing PUFA in free acid form |
07 Feb, 2025
(a month from now)
| Active |
| US9012501 | Type A gelatin capsule containing PUFA in free acid form |
07 Feb, 2025
(a month from now)
| Active |
| US9132112 | Type A gelatin capsule containing PUFA in free acid form |
07 Feb, 2025
(a month from now)
| Active |
| US5792795 | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
13 May, 2020
(4 years ago)
| Expired |
| US5948818 | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
13 May, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epanova's drug page
7. Faslodex
Faslodex is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6774122
(Pediatric)
| Formulation |
09 Jul, 2021
(3 years ago)
| Expired |
| US7456160
(Pediatric)
| Formulation |
09 Jul, 2021
(3 years ago)
| Expired |
| US8329680
(Pediatric)
| Formulation |
09 Jul, 2021
(3 years ago)
| Expired |
| US8466139
(Pediatric)
| Formulation |
09 Jul, 2021
(3 years ago)
| Expired |
| US6774122 | Formulation |
09 Jan, 2021
(3 years ago)
| Expired |
| US7456160 | Formulation |
09 Jan, 2021
(3 years ago)
| Expired |
| US8329680 | Formulation |
09 Jan, 2021
(3 years ago)
| Expired |
| US8466139 | Formulation |
09 Jan, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Faslodex's drug page
8. Iressa
Iressa is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5770599 | Quinazoline derivatives |
05 May, 2017
(7 years ago)
| Expired |
| US5457105 | Quinazoline derivatives useful for treatment of neoplastic disease |
19 Jan, 2013
(11 years ago)
| Expired |
| US5616582 | Quinazoline derivatives as anti-proliferative agents |
19 Jan, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Iressa's drug page
9. Koselugo
Koselugo is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11813246 | Pharmaceutical composition |
26 Mar, 2029
(4 years from now)
| Active |
| US9156795 | Hydrogen sulfate salt |
12 Dec, 2026
(1 year, 11 months from now)
| Active |
| US9562017 | Hydrogen sulfate salt |
12 Dec, 2026
(1 year, 11 months from now)
| Active |
| US7425637 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
13 Mar, 2025
(2 months from now)
| Active |
| US8178693 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
13 Mar, 2025
(2 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Koselugo's drug page
10. Lokelma
Lokelma is protected by 15 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10300087 | Extended use zirconium silicate compositions and methods of use thereof |
14 Oct, 2035
(10 years from now)
| Active |
| US11738044 | Extended use zirconium silicate compositions and methods of use thereof |
14 Oct, 2035
(10 years from now)
| Active |
| US9592253 | Extended use zirconium silicate compositions and methods of use thereof |
14 Oct, 2035
(10 years from now)
| Active |
| US10695365 | Microporous zirconium silicate for the treatment of hyperkalemia |
22 Oct, 2033
(8 years from now)
| Active |
| US8877255 | Microporous zirconium silicate for the treatment of hyperkalemia |
22 Oct, 2033
(8 years from now)
| Active |
| US9913860 | Microporous zirconium silicate for the treatment of hyperkalemia |
22 Oct, 2033
(8 years from now)
| Active |
| US8802152 | Microporous zirconium silicate for the treatment of hyperkalemia |
19 Apr, 2032
(7 years from now)
| Active |
| US10335432 | Microporous zirconium silicate for the treatment of hyperkalemia |
10 Feb, 2032
(7 years from now)
| Active |
| US10398730 | Microporous zirconium silicate for the treatment of hyperkalemia |
10 Feb, 2032
(7 years from now)
| Active |
| US10413569 | Microporous zirconium silicate for the treatment of hyperkalemia |
10 Feb, 2032
(7 years from now)
| Active |
| US11406662 | Microporous zirconium silicate for the treatment of hyperkalemia |
10 Feb, 2032
(7 years from now)
| Active |
| US8808750 | Microporous zirconium silicate for the treatment of hyperkalemia |
10 Feb, 2032
(7 years from now)
| Active |
| US9844567 | Microporous zirconium silicate for the treatment of hyperkalemia |
10 Feb, 2032
(7 years from now)
| Active |
| US9861658 | Microporous zirconium silicate for the treatment of hyperkalemia |
10 Feb, 2032
(7 years from now)
| Active |
| US6332985 | Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions |
29 Mar, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lokelma's drug page
11. Lynparza
Lynparza is protected by 16 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11970530 | Methods of treating homologous recombination deficient cancer |
25 Oct, 2041
(16 years from now)
| Active |
| US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
04 Aug, 2031
(6 years from now)
| Active |
| US8475842 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
31 Dec, 2029
(5 years from now)
| Active |
| US11633396 | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one |
07 Oct, 2029
(4 years from now)
| Active |
| US11975001 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
07 Oct, 2029
(4 years from now)
| Active |
| US12048695 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
07 Oct, 2029
(4 years from now)
| Active |
| US8247416 | Phthalazinone derivative |
24 Sep, 2028
(3 years from now)
| Active |
| US7449464 | Phthalazinone derivatives |
08 Sep, 2027
(2 years from now)
| Active |
| US8071579 | DNA damage repair inhibitors for the treatment of cancer |
12 Aug, 2027
(2 years from now)
| Active |
| US8143241 | DNA damage repair inhibitors for treatment of cancer |
12 Aug, 2027
(2 years from now)
| Active |
| US7449464 | Phthalazinone derivatives |
11 Oct, 2024
(2 months ago)
| Expired |
| US7981889 | Phthalazinone derivatives |
11 Oct, 2024
(2 months ago)
| Expired |
| US8912187 | Phthalazinone derivatives |
12 Mar, 2024
(9 months ago)
| Expired |
| US9169235 | Phthalazinone derivatives |
12 Mar, 2024
(9 months ago)
| Expired |
| US9566276 | Phthalazinone derivatives |
12 Mar, 2024
(9 months ago)
| Expired |
| US7151102 | Phthalazinone derivatives |
29 Apr, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lynparza's drug page
12. Nexium
Nexium is protected by 24 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6428810
(Pediatric)
| Pharmaceutical formulation comprising omeprazole |
03 May, 2020
(4 years ago)
| Expired |
| US6428810 | Pharmaceutical formulation comprising omeprazole |
03 Nov, 2019
(5 years ago)
| Expired |
| US6147103
(Pediatric)
| Omeprazole process and compositions thereof |
09 Apr, 2019
(5 years ago)
| Expired |
| US6166213
(Pediatric)
| Omeprazole process and compositions thereof |
09 Apr, 2019
(5 years ago)
| Expired |
| US6191148
(Pediatric)
| Omerazole process and compositions thereof |
09 Apr, 2019
(5 years ago)
| Expired |
| US6369085
(Pediatric)
| Form of S-omeprazole |
25 Nov, 2018
(6 years ago)
| Expired |
| US7411070
(Pediatric)
| Form of S-omeprazole |
25 Nov, 2018
(6 years ago)
| Expired |
| US8466175
(Pediatric)
| Form of S-omeprazole |
25 Nov, 2018
(6 years ago)
| Expired |
| US6147103 | Omeprazole process and compositions thereof |
09 Oct, 2018
(6 years ago)
| Expired |
| US6166213 | Omeprazole process and compositions thereof |
09 Oct, 2018
(6 years ago)
| Expired |
| US6191148 | Omerazole process and compositions thereof |
09 Oct, 2018
(6 years ago)
| Expired |
| US6369085 | Form of S-omeprazole |
25 May, 2018
(6 years ago)
| Expired |
| US7411070 | Form of S-omeprazole |
25 May, 2018
(6 years ago)
| Expired |
| US8466175 | Form of S-omeprazole |
25 May, 2018
(6 years ago)
| Expired |
| US5900424
(Pediatric)
| Omeprazole magnesium salt form |
04 Nov, 2016
(8 years ago)
| Expired |
| US5900424 | Omeprazole magnesium salt form |
04 May, 2016
(8 years ago)
| Expired |
| US5714504
(Pediatric)
| Compositions |
03 Aug, 2015
(9 years ago)
| Expired |
| US5690960
(Pediatric)
| Pharmaceutical formulation of omeprazole |
25 May, 2015
(9 years ago)
| Expired |
| US5714504 | Compositions |
03 Feb, 2015
(9 years ago)
| Expired |
| US5877192
(Pediatric)
| Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
27 Nov, 2014
(10 years ago)
| Expired |
| US6875872
(Pediatric)
| Compounds |
27 Nov, 2014
(10 years ago)
| Expired |
| US5690960 | Pharmaceutical formulation of omeprazole |
25 Nov, 2014
(10 years ago)
| Expired |
| US5877192 | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
27 May, 2014
(10 years ago)
| Expired |
| US6875872 | Compounds |
27 May, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexium's drug page
13. Nexium Iv
Nexium Iv is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5877192
(Pediatric)
| Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
27 Nov, 2014
(10 years ago)
| Expired |
| US5877192 | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
27 May, 2014
(10 years ago)
| Expired |
| US6143771 | Compounds |
27 May, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexium Iv's drug page
14. Prilosec
Prilosec is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6150380
(Pediatric)
| Crystalline form of omeprazole |
10 May, 2019
(5 years ago)
| Expired |
| US6147103
(Pediatric)
| Omeprazole process and compositions thereof |
09 Apr, 2019
(5 years ago)
| Expired |
| US6166213
(Pediatric)
| Omeprazole process and compositions thereof |
09 Apr, 2019
(5 years ago)
| Expired |
| US6191148
(Pediatric)
| Omerazole process and compositions thereof |
09 Apr, 2019
(5 years ago)
| Expired |
| US6150380 | Crystalline form of omeprazole |
10 Nov, 2018
(6 years ago)
| Expired |
| US6147103 | Omeprazole process and compositions thereof |
09 Oct, 2018
(6 years ago)
| Expired |
| US6166213 | Omeprazole process and compositions thereof |
09 Oct, 2018
(6 years ago)
| Expired |
| US6191148 | Omerazole process and compositions thereof |
09 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prilosec's drug page
15. Prilosec Otc
Prilosec Otc is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6403616 | Chemical process and pharmaceutical formulation |
15 Nov, 2019
(5 years ago)
| Expired |
| US6428810 | Pharmaceutical formulation comprising omeprazole |
03 Nov, 2019
(5 years ago)
| Expired |
| US5900424 | Omeprazole magnesium salt form |
04 May, 2016
(8 years ago)
| Expired |
| US5817338 | Multiple unit tableted dosage form of omeprazole |
06 Oct, 2015
(9 years ago)
| Expired |
| US5753265 | Multiple unit pharmaceutical preparation |
07 Jun, 2015
(9 years ago)
| Expired |
| US5690960 | Pharmaceutical formulation of omeprazole |
25 Nov, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prilosec Otc's drug page
16. Pulmicort Respules
Pulmicort Respules is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6598603
(Pediatric)
| Method for treating respiratory diseases |
23 Jun, 2019
(5 years ago)
| Expired |
| US6899099
(Pediatric)
| Method for treating a respiratory disease |
23 Jun, 2019
(5 years ago)
| Expired |
| US7524834
(Pediatric)
| Sterile powders, formulations, and methods for producing the same |
11 May, 2019
(5 years ago)
| Expired |
| US6598603 | Method for treating respiratory diseases |
23 Dec, 2018
(6 years ago)
| Expired |
| US6899099 | Method for treating a respiratory disease |
23 Dec, 2018
(6 years ago)
| Expired |
| US7524834 | Sterile powders, formulations, and methods for producing the same |
11 Nov, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pulmicort Respules's drug page
17. Rhinocort
Rhinocort is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6291445
(Pediatric)
| Low dose budesonide formulations and uses thereof |
29 Oct, 2017
(7 years ago)
| Expired |
| US6686346
(Pediatric)
| Formulation |
29 Oct, 2017
(7 years ago)
| Expired |
| US6986904
(Pediatric)
| Formulation |
29 Oct, 2017
(7 years ago)
| Expired |
| US6291445 | Low dose budesonide formulations and uses thereof |
29 Apr, 2017
(7 years ago)
| Expired |
| US6686346 | Formulation |
29 Apr, 2017
(7 years ago)
| Expired |
| US6986904 | Formulation |
29 Apr, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rhinocort's drug page
18. Seroquel Xr
Seroquel Xr is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5948437
(Pediatric)
| Pharmaceutical compositions using thiazepine |
28 Nov, 2017
(7 years ago)
| Expired |
| US5948437 | Pharmaceutical compositions using thiazepine |
28 May, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Seroquel Xr's drug page
19. Symbicort
Symbicort is protected by 33 patents, out of which 24 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8616196
(Pediatric)
| Inhalation device and a method for assembling said inhalation device |
07 Oct, 2029
(4 years from now)
| Active |
| US8528545
(Pediatric)
| Inhaler device that reduces the risk for miscounting a dosage |
16 Apr, 2029
(4 years from now)
| Active |
| US8616196 | Inhalation device and a method for assembling said inhalation device |
07 Apr, 2029
(4 years from now)
| Active |
| US8528545 | Inhaler device that reduces the risk for miscounting a dosage |
16 Oct, 2028
(3 years from now)
| Active |
| US8387615
(Pediatric)
| Inhaler cap strap |
26 Sep, 2027
(2 years from now)
| Active |
| US8387615 | Inhaler cap strap |
26 Mar, 2027
(2 years from now)
| Active |
| US7587988
(Pediatric)
| Inhaler device counter |
10 Oct, 2026
(1 year, 9 months from now)
| Active |
| US7587988 | Inhaler device counter |
10 Apr, 2026
(1 year, 3 months from now)
| Active |
| US8875699
(Pediatric)
| Inhaler cap strap |
10 May, 2025
(4 months from now)
| Active |
| US8875699 | Inhaler cap strap |
10 Nov, 2024
(a month ago)
| Expired |
| US10166247
(Pediatric)
| Composition for inhalation |
29 Jul, 2023
(1 year, 4 months ago)
| Expired |
| US11311558
(Pediatric)
| Composition for inhalation |
29 Jul, 2023
(1 year, 4 months ago)
| Expired |
| US7759328
(Pediatric)
| Composition for inhalation |
29 Jul, 2023
(1 year, 4 months ago)
| Expired |
| US8143239
(Pediatric)
| Composition for inhalation |
29 Jul, 2023
(1 year, 4 months ago)
| Expired |
| US8575137
(Pediatric)
| Composition for inhalation |
29 Jul, 2023
(1 year, 4 months ago)
| Expired |
| US10166247 | Composition for inhalation |
29 Jan, 2023
(1 year, 10 months ago)
| Expired |
| US11311558 | Composition for inhalation |
29 Jan, 2023
(1 year, 10 months ago)
| Expired |
| US7759328 | Composition for inhalation |
29 Jan, 2023
(1 year, 10 months ago)
| Expired |
| US8143239 | Composition for inhalation |
29 Jan, 2023
(1 year, 10 months ago)
| Expired |
| US8575137 | Composition for inhalation |
29 Jan, 2023
(1 year, 10 months ago)
| Expired |
| US7967011
(Pediatric)
| Inhalation device |
11 Feb, 2022
(2 years ago)
| Expired |
| US7967011 | Inhalation device |
11 Aug, 2021
(3 years ago)
| Expired |
| US7367333
(Pediatric)
| Inhalation device |
11 May, 2019
(5 years ago)
| Expired |
| US7897646
(Pediatric)
| Use for budesonide and formoterol |
09 Mar, 2019
(5 years ago)
| Expired |
| US8461211
(Pediatric)
| Use for budesonide and formoterol |
09 Mar, 2019
(5 years ago)
| Expired |
| US7367333 | Inhalation device |
11 Nov, 2018
(6 years ago)
| Expired |
| US7897646 | Use for budesonide and formoterol |
09 Sep, 2018
(6 years ago)
| Expired |
| US8461211 | Use for budesonide and formoterol |
09 Sep, 2018
(6 years ago)
| Expired |
| US6123924
(Pediatric)
| Pressurized aerosol inhalation compositions |
26 Mar, 2018
(6 years ago)
| Expired |
| US6123924 | Pressurized aerosol inhalation compositions |
26 Sep, 2017
(7 years ago)
| Expired |
| US5674860 | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders |
07 Oct, 2014
(10 years ago)
| Expired |
| US5972919 | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof |
17 Dec, 2012
(12 years ago)
| Expired |
| US6641800 | Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane |
23 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symbicort's drug page
20. Symbicort Aerosphere
Symbicort Aerosphere is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10716753 | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
28 May, 2030
(5 years from now)
| Active |
| US9415009 | Compositions, methods and systems for respiratory delivery of two or more active agents |
28 May, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symbicort Aerosphere's drug page
21. Tagrisso
Tagrisso is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10183020 | Pharmaceutical compositions comprising AZD9291 |
02 Jan, 2035
(10 years from now)
| Active |
| US8946235 | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
08 Aug, 2032
(7 years from now)
| Active |
| US11524951 | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
25 Jul, 2032
(7 years from now)
| Active |
| US9732058 | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
25 Jul, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tagrisso's drug page
22. Truqap
Truqap is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039766 | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide |
16 Apr, 2033
(8 years from now)
| Active |
| US9487525 | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide |
16 Apr, 2033
(8 years from now)
| Active |
| US8101623 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor |
10 Mar, 2030
(5 years from now)
| Active |
| US10059714 | Protein kinase B inhibitors |
10 Oct, 2028
(3 years from now)
| Active |
| US10654855 | Protein kinase B inhibitors |
10 Oct, 2028
(3 years from now)
| Active |
| US11760760 | Protein kinase B inhibitors |
10 Oct, 2028
(3 years from now)
| Active |
| US8809336 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors |
25 Oct, 2025
(10 months from now)
| Active |
| US9006430 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein |
25 Oct, 2025
(10 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Truqap's drug page
23. Zomig-zmt
Zomig-zmt is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5466699
(Pediatric)
| Indolyl compounds for treating migraine |
14 May, 2013
(11 years ago)
| Expired |
| US5466699 | Indolyl compounds for treating migraine |
14 Nov, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zomig-zmt's drug page